Skip to main content
. 2022 Apr 27;62(9):1170–1176. doi: 10.1002/jcph.2056

Figure 3.

Figure 3

Coverage of estimated CSF Css,avg over ALK inhibition targets in patients receiving 100 mg QD lorlatinib dosing and a confirmed L1196M (a) or G1202R (b) mutation. The green line shows the unbound target concentrations for L1196M (21.08 ng/mL) inhibition. The red line shows the unbound target concentrations for G1202R (67.06 ng/mL) inhibition. 29 ALK, anaplastic lymphoma kinase; CSF, cerebrospinal fluid; Css,avg, average steady‐state plasma concentration; QD, once daily.